Study of Different Phenotypes of Polycystic Ovarian Disease and their Effects on Clomiphene Resistance in Infertile Women
- 1. Assistant Professor, Department of Obstetrics and Gynaecology, Sri Krishna Medical College and Hospital, Muzaffarpur, Bihar
- 2. Senior Resident, Department of Obstetrics and Gynaecology, Sri Krishna Medical College and Hospital, Muzaffarpur, Bihar
- 3. Professor and Principal, Department of Obstetrics and Gynaecology, Sri Krishna Medical College & Hospital, Muzaffarpur, Bihar
Description
Background: One significant issue facing infertile women with polycystic ovarian disease (PCOD) is clomi-phene resistance. Patients would have a better prognosis if the causes were identified. The purpose of this study was to identify the various PCOD phenotypes and how they affected infertile women’s clomiphene resistance. Methods: The Department of Obstetrics and Gynaecology, SKMCH, Muzaffarpur, Bihar, referred 100 consecu-tive PCOD women with infertility who was taking clomiphene from Sadar Hospital and private nursing homes between August 2023 and January 2024. The study was a descriptive-comparative cross-sectional study. The impact of various PCOD phenotypes on these women’s clomiphene resistance was evaluated. Results: According to the findings, 39 (39.0%), 7 (7.0%), 26 (26.0%), and 28 (28.0%) patients, respectively, exhibited the A, B, C, and D phenotypes. Resistance was present in 31 patients (31%). A (HA+OA+PCO) was the most prevalent PCOD phenotype, observed in 48.4% of patients, while D (OA+PCO) was shown in 25.8% of patients. However, there was no significant difference in the phenotypes (P=0.064). Conclusion: According to the results, there was no significant association between PCOD phenotypes and clomiphene resistance. Finally, A and D phenotypes were frequent types with clomiphene resistance.
Abstract (English)
Background: One significant issue facing infertile women with polycystic ovarian disease (PCOD) is clomi-phene resistance. Patients would have a better prognosis if the causes were identified. The purpose of this study was to identify the various PCOD phenotypes and how they affected infertile women’s clomiphene resistance. Methods: The Department of Obstetrics and Gynaecology, SKMCH, Muzaffarpur, Bihar, referred 100 consecu-tive PCOD women with infertility who was taking clomiphene from Sadar Hospital and private nursing homes between August 2023 and January 2024. The study was a descriptive-comparative cross-sectional study. The impact of various PCOD phenotypes on these women’s clomiphene resistance was evaluated. Results: According to the findings, 39 (39.0%), 7 (7.0%), 26 (26.0%), and 28 (28.0%) patients, respectively, exhibited the A, B, C, and D phenotypes. Resistance was present in 31 patients (31%). A (HA+OA+PCO) was the most prevalent PCOD phenotype, observed in 48.4% of patients, while D (OA+PCO) was shown in 25.8% of patients. However, there was no significant difference in the phenotypes (P=0.064). Conclusion: According to the results, there was no significant association between PCOD phenotypes and clomiphene resistance. Finally, A and D phenotypes were frequent types with clomiphene resistance.
Files
IJPCR,Vol16,Issue6,Article59.pdf
Files
(333.1 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:5111871a2ad3b74a4af05f039970942b
|
333.1 kB | Preview Download |
Additional details
Dates
- Accepted
-
2024-05-26
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/16/IJPCR,Vol16,Issue6,Article59.pdf
- Development Status
- Active
References
- 1. Frank S. Polycystic ovary syndrome. N Engl J Med. 1995; 333: 853-61. 2. Azziz R, Woods KS, Reyna R, Key TJ, Kenochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary in an unselected population. J Clin Endocrinol Metab. 2004; 89: 2745-9. 3. Rotterdam ESHRE-ASRM sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Human Reprod. 2004; 19:41-7. 4. Gupta M SD, Toppo M, Priya A, Sethia S, Gupta P. A cross sectional study of polycystic ovarian syndrome among young women in Bhopal, Central India. Int J Community Med Public Health 2018; 5:95-100. 5. Balen A. The pathophysiology of polycystic ovary syndrome: trying to understand PCOS and its endocrinology. Best Pract Res Clin Obstet Gynaecol. 2004; 18(5):685-706. 6. Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Casson P, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med. 2014;371(2):119-29. 7. Hajishafiha M, Dehghan M, Kiarang N, Sadegh-Asadi N, Shayegh SN, Ghasemi-Rad M. Combined letrozole and clomiphene versus letrozole and clomiphene alone in infertile pa-tients with polycystic ovary syndrome. Drug Des Devel Ther. 2013; 7:1427-31. 8. Roy KK, Baruah J, Singla S, Sharma JB, Singh N, Jain SK, et al. A prospective randomized trial comparing the efficacy of Letrozole and Clomiphene citrate in induction of ovulation in polycystic ovarian syndrome. J Hum Reprod Sci. 2012;5(1):20-5. 9. Abdali F, Taghavi S, Vazifekhah S, Naghavi Behzad M, Mirza Aghazadeh Attari M. Effect of Progesterone on Latent Phase Prolongation in Patients with Preterm Premature Rupture of Membranes. Acta Med Iran. 2017; 55(12):772- 778. 10. Saha L, Kaur S, Saha PK. N-acetyl cysteine in clomiphene citrate resistant polycystic ovary syndrome: A review of reported outcomes. J Pharmacol Pharmacother. 2013;4(3):187-91. 11. Brown J, Farquhar C. Clomiphene and other antioestrogens for ovulation induction in polycystic ovarian syndrome. Cochrane Database Syst Rev. 2016;15;12:CD002249. 12. Nasseri S, Ledger WL. Clomiphene citrate in the twenty-first century. Hum Fertil (Camb). 2001;4(3):145-51. 13. Dasari P, Pranahita G. The efficacy of metformin and clomiphene citrate combination compared with clomiphene citrate alone for ovulation induction in infertile patients with PCOS. J Hum Reprod Sci. 2009;2(1):18-22. 14. Chang WY, Knochenhauer ES, Bartolucci AA, Azziz R. Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups. Fertil Steril. 2005;83(6):1717-30. 15. Carmina E, Azziz R. Diagnosis, phenotype, and prevalence of polycystic ovary syndrome. FertilSteril. 2006;86 Suppl 1:S7-8. 16. Seyedoshohadaei F, Zandvakily F, Shahgeibi S. Comparison of the effectiveness of clomiphene citrate, tamoxifen and letrozole in ovulation induction in infertility due to isolated unovulation. Iran J Reprod Med. 2012;10(6):531- 6. 17. Ramezanali F, Ashrafi M, Hemat M, Arabipoor A, Jalali S, Moini A. Assisted reproductive outcomes in women with different polycystic ovary syndrome phenotypes: the predictive value of anti-Müllerian hormone. Reprod Biomed Online. 2016;32(5):503-12. 18. Ciftci CF, Uckuyu A, Karadeli E, Turhan E, Toprak E, Ozcimen EE. Phenotypic subgroups of polycystic ovary syndrome have different intra-renal resistance symptoms. Ginekol Pol. 2012;83(12):910-5. 19. Pehlivanov B, Orbetzova M. Characteristics of different phenotypes of polycystic ovary syndrome in a Bulgarian population. GynecolEndocrinol. 2007;23(10):604-9. 20. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med. 1998; 338(26):1876-80. 21. Rouzi AA, Ardawi MS. A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate–resistant polycystic ovary syndrome. FertilSteril. 2006;85(2):428-35. 22. Palomba S, Pasquali R, OrioJr F, Nestler JE. Clomiphene citrate, metformin or both as first‐step approach in treating anovulatory infertility in patients with polycystic ovary syndrome (PCOS): a systematic review of head‐to‐head randomized controlled studies and meta‐analysis. Clin Endocrinol. 2009; 70(2): 311-21. 23. Ellakwa HE, Sanad ZF, Hamza HA, Emara MA, Elsayed MA. Predictors of patient responses to ovulation induction with clomiphene citrate in patients with polycystic ovary syndrome experiencing infertility. Int J Gynaecol Obstet. 2016;133(1):59-63. 24. Abu Hashim H, Foda O, Ghayaty E. Combined metformin‐clomiphene in clomiphene‐resistant polycystic ovary syndrome: a systematic review and meta‐analysis of randomized controlled trials. Acta Obstet Gynecol Scand. 2015; 94(9):921-30.